spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  toxin A 

 HSMN NewsFeed - 22 Jun 2023
Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 7 Feb 2022
Vensica Closes $19 Million Round with Investment from Strategic Partner Merz
Devices Drug Delivery Urology Venture Capital
 HSMN NewsFeed - 23 Dec 2021
Healis Therapeutics announces mission to deliver new class of neuromuscular treatments in psychiatry
Biopharmaceuticals
 HSMN NewsFeed - 1 Nov 2021
Vensica Therapeutics Closes $16 Million Investment Round
Devices Drug Delivery Urology Venture Capital
 HSMN NewsFeed - 22 Jun 2020
FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX(R) (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 18 Dec 2019
Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality(R) (galcanezumab-gnlm)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Jul 2019
Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX(R) Platform Technology
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 May 2018
GT Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Apr 2018
Seasoned Financial Executive Federica O'Brien Joins GT Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Apr 2018
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Feb 2018
GT Biopharma Announces Appointment of Shawn M Cross as Chairman and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Jan 2018
Geoffrey B. Davis Joins GT Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Jul 2017
Luminex Corporation Receives FDA Clearance for ARIES C. difficile Assay
Diagnostics FDA
 HSMN NewsFeed - 5 Dec 2016
Spectral Announces Appointment of Dr. Masayuki Kaneko to Its Board of Directors
Devices Personnel
 HSMN NewsFeed - 1 Aug 2016
Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport(R) (Abobotulinumtoxin A) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Aug 2016
Ipsen Announces FDA Approval of Dysport(R) (abobotulinumtoxinA) for Injection for the Treatment of Lower Limb Spasticity in Children Aged Two and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Oct 2015
Spectral and Toray Medical Sign Exclusive EAA(TM) Distribution Agreement for 15 Countries in the Middle and Far East
Diagnostics Distribution
 HSMN NewsFeed - 3 Jul 2015
Revance Therapeutics Announces Change in Role of Jacob Waugh, M.D.
Biopharmaceuticals Drug Delivery Dermatology Personnel
 HSMN NewsFeed - 5 Nov 2014
Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 23 Sep 2014
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Mar 2014
Revance to Add Angus C. Russell as Chairman to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Feb 2014
Ipsen announces clinical results of Dysport(R) Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW(1)
Biopharmaceuticals
 HSMN NewsFeed - 6 Jan 2014
Soligenix Appoints Richard Straube, MD, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Oct 2013
Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Oct 2013
Soligenix Appoints Oreola Donini, PhD, as Vice President of Preclinical Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Sep 2013
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Mar 2013
Revance Therapeutics Announces Appointment of Lauren Silvernail as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Feb 2013
FDA Grants QIDP and Fast Track Designations for Cubist’s Late-Stage Antibiotic Candidates
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jan 2013
FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Jan 2013
FDA Grants Soligenix Orphan Drug Designation for OrbeShield(TM) for Treatment after Exposure to a Radiological Disaster
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Mar 2012
Myoscience Closes $33 Million Series D Financing
Devices Venture Capital
 HSMN NewsFeed - 13 Aug 2010
US WorldMeds Acquires Solstice Neurosciences
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 4 Aug 2009
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jun 2009
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Biopharmaceuticals
 HSMN NewsFeed - 21 Apr 2009
Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile Infection
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Mar 2009
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jan 2009
DOR BioPharma Obtains Fast Track Designation for DOR201 in the Prevention of Acute Radiation Enteritis
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2008
DOR BioPharma Forms orBec(R) European Medical Advisory Board
Biopharmaceuticals
 HSMN NewsFeed - 4 Aug 2008
Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in Russia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 May 2008
DOR BioPharma Opens New Corporate Office in United Kingdom
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2008
DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy
Biopharmaceuticals
 HSMN NewsFeed - 7 Jan 2008
Alkermes Announces Agreement for the Commercialization of VIVITROL in Russia/CIS
Biopharmaceuticals
 HSMN NewsFeed - 3 Jan 2008
DOR BioPharma Receives Orphan Drug Designation for Oral BDP for the Treatment of Pediatric Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 7 Dec 2007
DOR BioPharma Announces Results of orBec(R) End of Review Conference With the FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Dec 2007
Ipsen Grants Galderma Exclusive Rights to Promote and Distribute Dysport(R) in Aesthetic Medicine and Dermatological Indications in Brazil, Argentina and Paraguay
Biopharmaceuticals Distribution Dermatology
 HSMN NewsFeed - 19 Oct 2007
DOR BioPharma Receives Not Approvable Letter From FDA for orBec(R) for Treatment of Gastrointestinal Graft-versus-Host Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Oct 2007
orBec(R) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2007
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Apr 2007
DOR BioPharma Announces Initiation of Clinical Development Program for Oral Leuprolide
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 27 Mar 2007
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Metastatic Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Mar 2007
DOR BioPharma Forms orBec(R) Medical Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Mar 2007
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa(TM) in Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Jan 2007
FDA Advisory Committee to Review DOR BioPharma's orBec(R) for the Treatment of GI GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Nov 2006
European Medicines Agency Accepts DOR BioPharma's MAA Filing for orBec(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Nov 2006
FDA Accepts DOR BioPharma's NDA Filing for orBec(R)
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 7 Nov 2006
DOR BioPharma Submits European Marketing Application for orBec(R) to Treat GI Graft-Versus-Host Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Oct 2006
Nephros Announces Positive Results of Clinical Study for Olpur MD190 Mid-Dilution Hemodiafiltration Filter
Devices
 HSMN NewsFeed - 22 Sep 2006
DOR BioPharma Files New Drug Application with FDA to Market orBec for GI GVHD
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 31

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 31 additional stories matching:
toxin A
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.